From the Agenda

Unlocking the value of biosimilars in Europe – the Commercial Perspective

2017-11-24 09:40

Adam Levysohn

Global Head Market Access, Biosimilar Business Unit

Adam is the Global Head of Biogens Biosimilars Business Unit Value and Access team and has been a member of the leadership team since the beginning. Adam has more than 15 years of experience in value and access. Prior to Biogen, he was at Novo Nordisk in global, regional and affiliate roles including head of the companys Global Market Access and Market Access Europe. Adam has also served as Global Market Access Director at Novartis, where he was responsible for Ilaris (canakinumab), and Head of Global Market Access at Takeda Pharmaceuticals, CardioMetabolic TA.